Clinical Trial Update: AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN [NA]

View source ↗

Summary

Completed AVERT trial evaluating whether reducing contrast media volume lowers the incidence of contrast-induced nephropathy; results were posted in early 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy

Drugs mentioned

• AVERT Contrast Media Reduction System

Snippet

Sponsor: Osprey Medical, Inc | Conditions: Contrast Induced Nephropathy (CIN) | NA | Status: COMPLETED | Results posted: 2017-01-02